Introduction
The incidence of coronary heart disease is dramatically increased when estrogen levels drop during menopause (1, 2) . Furthermore, the protective action of exogenous estrogen has been shown in animal and human studies (3) (4) (5) . Although estrogen prevents the development of atherosclerosis by lowering plasma cholesterol (6) , it has been shown to have a direct effect on the arterial wall (7) . Moreover, recent studies demonstrated that estrogen also has a protective effect against ischemic brain damage (8, 9) . However, the mechanisms underlying the protective effect of estrogen are yet to be elucidated.
Nitric oxide (NO) is a key modulator of vasodilation, and inhibits the activation of platelet and leukocyte. Recent evidence suggested that NO production may play an important role in the effects of estrogen on the vasculature (10) (11) (12) . Endothelium-derived NOdependent vasorelaxation has been shown to be increased after the treatment with 17B-estradiol in various arteries, including coronary artery and aorta (10, 13, 14) . Moreover, 1713-estradiol has been shown to induce the expression of endothelial isoform of NO synthase (12, 15, 16) .
Tetrahydrobiopterin (BH4) is an essential cofactor for NO synthesis, and increase in BH4 level in vascular endothelial cells seems to stimulate NO production (17) . Moreover, BH4 has an antioxidative activity, and protects bovine vascular endothelial cells and rat hepatocytes against reactive oxygen species (ROS)-induced cell injury (18, 19) . Thus, BH4 is not only one of the cofactors of NO synthase, but also an intracellular antioxidant. It is reported that antioxidative activity seems to be implicated in the protective effect of estrogen against ischemic brain damage (8,9) . Therefore, we hypothesized that the protective effect of estrogen is mediated by an increase in BH4 level in vascular endothelial cells. In the present study, to evaluate our hypothesis, we examined the effect of 1713-estradiol on BH4 synthesis in vascular endothelial cells.
Methods

Cell culture
Mouse brain microvascular endothelial cells (2nd passage) were purchased from Toyobo Co. (Osaka, Japan). The cells were cultured in Dulbecco's modified Eagle medium containing 10% fetal bovine serum, 100 U/ml penicillin and 100 flg/ml streptomycin. Cells were finally grown in 6-well plates to measure BH4 content or, in 60-mm culture dishes to extract total mRNA , and used for experiments when they reached confluence. The cells at 5 to 10 passages after purchase were used throughout all experiments .
Measurem ent of biopterin BH4 content was determined by oxidation under acidic conditions as biopterin and analysis with reversed-phase high performance liquid chromatography (HPLC) using fluorometric detection, as previously described (20) . Confluent endothelial cells in 6-well plates were washed three times with physiological saline solution (PSS, pH 7.4) containing 118.5 mM NaCl, 4.74 mM KCI, 2.5 mM CaCI 2 , 1.18 mM MgS0 4 , 1.18 mM KH 2 P0 4 , 2 .5 mM NaHC0 3 , 11 mM glucose and 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), and then treated with 171)-estradiol at 37°C in 2 ml of PSS. After the treatment with 171)-estradiol, intracellular BH4 was released by the addition of 10% trichloroacetic acid on ice for 30 min. Each sample was oxidized with Mn02_ and loaded on to HPLC.
M easurement of mRNA level of GTPCH by reverse transcriptase (RT)-PCR
Confluent endothelial cells in 60-mm dishes were washed three times with PSS . The washed cells were then treated with 1713-estradiol at 37°C in 3 ml ofPSS. Total RNA was extracted from the cells by a modified guanidinum isothiocyanate method with ISOGEN Reagent (Nippon Gene Co., Ltd., Tokyo, Japan). Reverse transcription and PCR amplification from 0.2 mg of total RNA were performed using rTth DNA polymerase (RT-PCR high Plus, Toyobo Co., Osaka, Japan). The primer pairs used for amplifications of GTPCH were 5'-GGATACCAGGAGACCATCTCA-3' and 5'-TAGCATGGTGCTAGTGACAGT-3'. The thermocycler was programmed for an initial cycle consisting of 60 0 C reverse transcription for 30 min and 94°C denaturation for 2 min, followed by 28 cycles of 94°C denaturation for 1 min and 58 0 C annealing/ extension for 1.5 min. As the control for the amounts of total RNA, parallel RT -PCR of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) rnRNA was perPteridineslVol. l llNo. 4 formed, using the primers 5'-TCCACCACCCT-GTTGCTGTA-3' and 5'-ACCACAGTCCATGCCAT-CAC-3'. PCR products were electrophoresed on a 3% agarose gel (Agarose S, Nippon Gene Co., Ltd. , Tokyo, Japan) containing ethidium bromide and visualized by UV -induced fluorescence.
Materials
1713-Estradiol and 4-hydroxy-tamoxifen were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). All other reagents were of the highest grade commercially available .
Statistical analysis
Values arc presented as mean ± S.E.M . of n observations. Differences between groups were assessed using analysis of variance followed by Bonfenoni's method. Differences among means were considered significant at P<0.05.
Results
Addition of 17f}-estradiol to mouse brain microvascular endothelial cells increased intracellular BH4 content in the time- (Fig . lA) and concentrations- (Fig.  1 B) dependent manner. Moreover, 1713-estradiol (30 roNI) increased the expression level of GTPCH mRNA , which is a rate-limiting enzyme of de novo BH4 synthetic pathway (Fig. 2) . The 1713-estradiol (30 rruVI)-induced GTPCH mRNA expression was strongly inhibited by the treatment with 4-hydroxy-tamoxifen (0.3 mM), which is an inhibitor of estrogen receptor (Fig. 3) . Total RNA was prepared from the cells, and the total RNA (0.2 I1g) was amplified by RT-PCR using primers for GTPCH or GAPDH. DNA size markers in the left-most lane correspond to (bp) : 525, 500, 400, 300.
Discussion
In the present study, we found that 1713-estradiol increases BH4 content in mouse brain microvascular endothelial cells. 1713-Estradiol also increased the mRNA level of GTPCH, which is a rate-limiting enzyme of de novo synthetic pathway of BH4. Moreover, the 17J3-estradiol-induced expression of GTPCH mRNA was reduced by 4-hydroxy-tamoxifen, an inhibitor of estrogen receptor. These findings strongly suggested that 17J3-estradiol stimulates BH4 synthesis through the induction of GTPCH by 4-hydroxy-tamoxifen-sensitive receptor.
Although the mechanisms are yet to be elucidated, estrogen has been shown to have a protective effect against various circulatory diseases, including ischemic brain injury (8, 9) . Recently, stimulation of NO production by estrogen has attracted considerable attention as one of the mechanisms of eSh'ogen-mediated protection. In fact, endothelial isoforrn of NO synthase is induced and activated by the treatment with 1713-estradiol in endothelial cells (12,15 , 16) , and 1713-estradiol affects the vasomotor responses through increasing the release of endothelium-dependent NO (10) . We previously showed that increase in BH4 content in bovine aortic endothelial cells stimulates Ca2~ ionophore-induced NO synthase actiVIty (18) . Although BH4, one of the co factors of NO synthase, has an impOltant role of NO production, it is not determined whether 1713-estradiol modulates BH4 synthesis. In the present study, we observed that 1713-estradiol stimulates BH4 synthesis. Theses observations strongly suggested that the stimulation of NO production by 1713-estradiol is accompanied with the i.nduction of BH4 synthesis.
Interestingly, BH4 has been shown to be not only one of the co factors of ~O synthase, but also intracellular antioxidant. \Ve previously showed that the increase in intracellular BH4 level reduces H 2 0 2 -induced intracellular oxidative stress using 2',7'-dichlorofluorescein, a hydroperoxide-sensitive dye, and strongly reduced H:0 2 -induced bovine aortic endothelial cell death (18) . Kojima et al. (19) reported that BH4 acts directly as a scavenger of superoxidc anion generated by xanthine/xanthine oxidase or by rat macrophage/phorbol myristate acetate radical-generating system. It is recognized that ROS are implicated in the development of various ischemic diseases, such as heart and brain, and development of atherosclerosis. The protective effect of estrogen against ischemic brain damage has been shown to be implicated in the antioxidative activity (9, 20) . It is possible that the anti oxidative effect of estrogen is perhaps mediated by increasing BH4. Interestingly, endothelial isofOlID of NO synthase released superoxide anion and H 2 0 2 instead of NO, when BH4 content was decreased (17, 22) . Thus, BH4 also has a regulatory role of NO synthase function . Therefore, it is possible that the protective effect of estrogen against various ischemic diseases may also be mediated by the reduction of ROSrelease from NO synthase by increasing BH4 level.
In conclusion, 1713-estradiol has a stimulatory effect on BH4 synthesis through the induction of GTPCH, which is a rate-limiting enzyme of the de novo synthetic pathway in BH4 synthesis, in brain microvascular endothelial cells. The stimulation of BH4 synthesis induced by 171J-estradiol may play an important role in exertion of its protective effect in various circulatory diseases, including ischemic brain diseases .
